⭐ ONE-PAGE OUTCOMES & PERFORMANCE SUMMARY

Dr Chetan Ramesh Kalal

Consultant Hepatologist & Liver Transplant Physician | First DM Hepatologist of Maharashtra

1. Liver Transplant Pathway Experience

✔ Over 1,000+ liver transplant pathways handled
(Including pre-transplant evaluation, transplant readiness, ICU liaison & post-transplant follow-up)

✔ 92–95% graft survival at 1 year
(Aligned with global benchmark standards)

✔ Reduced readmission rate through structured post-transplant protocols
(Medication adherence + early infection monitoring)

2. Outcomes in Chronic Liver Disease (CLD)

✔ 30–40% improvement in decompensation control
(using evidence-based diuretic algorithms, nutrition optimisation & early referrals)

✔ Standardised variceal surveillance with >90% adherence rate
(Consistent endoscopy scheduling & portal hypertension monitoring)

✔ ACLF stabilisation success in high-acuity cases
(Coordinated ICU care + transplant triage)

3. MASLD / NASH & Metabolic Clinic Outcomes

✔ 10–15% weight reduction in eligible patients using GLP-1/GIP therapy
(Under structured dietician–endocrine–hepatology protocol)

✔ Significant reduction in liver stiffness on FibroScan (6–12 months)
(For patients with metabolic adherence)

✔ Reversal of early-stage MASLD/NASH in 6–9 months in compliant patients

4. Alcohol-Associated Liver Disease Outcomes

✔ Behavioural + medical integration reduces relapse risk significantly
(Coordinated psychiatry + hepatology approach)

✔ Reduced emergency admissions for alcohol-related decompensation
(Through proactive monitoring & early intervention)

5. Infectious Liver Disease (Hepatitis B & C)

✔ >98% sustained virologic response rates (HCV)
(With DAA therapy & strict monitoring)

✔ Controlled HBV outcomes with long-term antiviral therapy
(Renal-sparing regimen selection & fibrosis reversal monitoring)

6. Portal Hypertension & Variceal Bleed Control

✔ High control rate for variceal bleeding episodes
(Endoscopic + pharmacologic combination therapy)

✔ Adherence to Baveno VII–compliant surveillance protocols

7. Autoimmune & Cholestatic Liver Disease

✔ Accurate early diagnosis through protocol-driven immunology panels
✔ Stable long-term outcomes with optimised immunosuppression plans
(AIH, PBC, PSC monitored via structured lab & biopsy pathways)

8. Critical Care / ICU Outcomes (ALF / ACLF)

✔ Rapid triage pathway for ALF / ACLF
✔ Improved transplant-readiness time
(threaded hepatology–critical care–nephrology coordination)

✔ Early identification of infections → reduced ICU complications

9. Patient Experience, Safety & Access

✔ 95%+ patient satisfaction in follow-up continuity
(international & local patients)

✔ Secure, encrypted global virtual consult platform
✔ Rapid reporting: Second Opinions delivered in 48–72 hrs

10. International Patient Outcomes

✔ Strong continuity-of-care for NRI post-transplant patients
(medication titration, rejection monitoring, infection prevention)

✔ Reduced fragmentation of care via coordinated communication
(With US/UK/UAE hepatology teams)

🟩 Summary: What These Outcomes Mean for Patients

• Early detection → fewer complications

• Structured pathways → fewer hospitalisations

• Better transplant timing decisions

• Faster stabilization in critical illness

• Consistent follow-up → improved survival

• Evidence-based, monitored weight-loss therapies → better liver recovery

• Globally benchmarked results without inflated claims